Leukemia, Lymphoma, and Myeloma

Multiple MyelomaA Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell TransplantPrincipal Investigator: Noffar Bar
Leukemia, otherA Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction ChemotherapyPrincipal Investigator: Thomas Prebet
Leukemia, not otherwise specified, Leukemia, other, PediatricsA Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLyPrincipal Investigator: Nina Kadan-Lottick
Myeloid and Monocytic LeukemiaA Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid LeukemiaPrincipal Investigator: Thomas Prebet
Multiple MyelomaDaratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)Principal Investigator: Noffar Bar